Treatment of Severe Clostridioides difficile Infection with Hypotension, Shock, or Ileus When High-Dose Vancomycin Does Not Achieve Clinical Improvement

In patients with severe C. difficile infection who develop hypotension, shock, ileus, or megacolon and fail to show the expected response to initial antibiotic therapy, a distinct next-line approach applies. This page describes that specific clinical situation and the evidence-based step that follows.

Clinical Scenario

Severe Clostridioides difficile infection with one or more of the following: hypotension, shock, ileus, or megacolon — defining criteria for fulminant infection.

Previous line — escalation trigger

The prior approach — high-dose vancomycin (with or without parenteral metronidazole, and vancomycin enemas in the setting of ileus) — did not achieve its target: clinical improvement within 48–72 hours. That failure of response is what indicates escalation to the protocol below.

Next-Line Approach

For fulminant CDI refractory to antibiotic therapy — particularly in patients who are poor surgical candidates — evidence supports a colonoscopic, microbiome-based intervention. Concurrent antibiotic therapy is maintained alongside this intervention for as long as the relevant colonic findings remain present. The complete sequence, timing, and accompanying measures are detailed in the full protocol.

Goal: Resolution of pseudomembrane in the colon

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000001278

We recommend defining fulminant infection as patients meeting criteria for severe C. difficile infection plus presence of hypotension or shock or ileus or megacolon.

We suggest FMT be considered for patients with severe and fulminant CDI refractory to antibiotic therapy, in particular, when patients are deemed poor surgical candidates (strong recommendation, low quality of evidence).

FMT should be repeated every 3–5 days until resolution of pseudomembrane.

Concomitantly, administration of oral vancomycin (125 mg every 6 hours) or fidaxomicin (200 mg every 12 hours) should be continued as long as pseudomembrane is present.

View source ↗